Important Note: This site is designed to work best in Firefox, Safari or Chrome. Please update your browser to view the complete site.

Board of Directors

JEFF EBERWEIN

Chairman of the Board

Mr. Eberwein has almost 25 years of Wall Street experience and is the Founder and CEO of Lone Star Value Management, LLC, an investment firm. Prior to founding Lone Star Value in January 2013, Mr. Eberwein was a Portfolio Manager at Soros Fund Management from January 2009 to December 2011 and Viking Global Investors from March 2005 to September 2008. Mr. Eberwein is Chairman of the Board of five public companies: Digirad Corporation, Hudson Global, Inc., a global recruitment company, AMERI Holdings Inc., an IT services company, Crossroads Systems, Inc., a data storage company, and ATRM Holdings, Inc., a modular building company. Mr. Eberwein also serves on the Board of Novation Companies, Inc., a communication software company. Mr. Eberwein served on the Board of The Goldfield Corporation from May 2012 until May 2013, On Track Innovations Ltd. from December 2012 until March 2014, and NTS, Inc. from December 2012 until its sale to a private equity firm was completed in June 2014. Mr. Eberwein served on the Board of Hope for New York, a 501(c)3 organization dedicated to serving the poor in New York City from 2011 until 2014 where he was Treasurer and on the Executive Committee. Mr. Eberwein earned a MBA from The Wharton School, University of Pennsylvania and a BBA with High Honors from The University of Texas at Austin.

 

DIMITRIOS J. ANGELIS

Director

Dimitrios J. Angelis was appointed as a director of the Company on July 30, 2015. In addition to Digirad, Mr. Angelis currently serves as a director of Ameri100, a post he’s held since May, 2015; and as director of On Track Innovations Ltd (“OTI”) since December 30, 2012. From April 26, 2013 until February 9, 2015, Mr. Angelis served as the OTI’s Chairman of the Board of Directors.

Mr. Angelis currently serves as the Chief Executive Officer of OTI America (a subsidiary of OTI). Since 2012 until immediately prior to his appointment as Chief Executive Officer of OTI America, Mr. Angelis was the General Counsel of Wockhardt Inc., a biologics and pharmaceutical company. From 2008 to 2012, Mr. Angelis was a senior counsel in Dr. Reddy’s Laboratories, Ltd., a publicly traded pharmaceutical company, and during 2008 he was the Chief Legal Officer and Corporate Secretary of Osteotech, Inc., a publicly traded medical device company. Prior to that, Mr. Angelis worked in the pharmaceutical industry in various corporate, strategic and legal roles. Mr. Angelis holds a B.A. in Philosophy and English from Boston College, an M.A. in Behavioral Science from California State University, and Juris Doctor from New York University School of Law.

 

JOHN M. CLIMACO

Director

Mr. Climaco, an attorney by training, is a consultant to a variety of healthcare companies. He is currently a board member at Digirad, a post he has held since December 2012. He also is a board member of Perma-Fix Environmental Services, Inc. (PESI), a publicly traded environmental solutions business, a post he has held since October 2013. Previously, he was a board member of PDI, Inc. (PDII), a publicly traded outsourced sales and marketing company, a post he held from December 2013 to October 2014. From April 2012 to April 2013, he was a board member of InfuSystem Holdings, Inc. (INFU), a publicly traded medical device and services company.

From 2003 to 2012, he was the President and Chief Executive Officer, as well as member of the board of directors, of Axial Biotech, Inc., a venture- backed molecular diagnostics company specializing in spine disorders, which he co-founded in 2003. Under Mr. Climaco’s leadership, and through partnerships he created with companies including Medtronic, Johnson & Johnson and Smith & Nephew, Axial successfully developed and commercialized ScoliScore, the first molecular prognostic test in the orthopaedic industry.

Prior to founding Axial Biotech, Mr. Climaco served as Director of Programming for Quokka Sports, a venture-backed online media company that went public in 1999. While with Quokka, Mr. Climaco helped to create and manage partnerships with Intel, Microsoft WebTV, NBC Sports and National Geographic. Mr. Climaco practiced law for 6 years with Fabian & Clendenin in Salt Lake City. Mr. Climaco holds a Bachelor of Arts in Philosophy, cum laude, from Middlebury College and a Juris Doctorate from the University of California, Hastings College of Law.

 

MIKE CUNNION

Director

 Mr. Cunnion has an extensive history of leadership roles at healthcare media and communication companies. Since September 2008, Mr. Cunnion has been President of Remedy Health Media, a privately held health media company. Prior to that, from January 2004 to December 2007, Mr. Cunnion was the President of privately held HealthTalk, leading provider of tools and information for chronically ill patients and caregivers. Mr. Cunnion successfully built this company and subsequently sold it to Revolution Health in December 2007. Subsequent to this sale, Mr. Cunnion took on the role of Executive Vice President of Revolution Health, where he oversaw revenue and sales strategy until Revolution Health merged with Everyday Health. Prior to HealthTalk, from December 1998 to December 2003, Mr. Cunnion held the role of Sr. Director, Consumer Marketing at WebMD, where he led consumer sales strategy, product development and advertising operations. Mr. Cunnion earned a B.A. degree in English from Florida State University.

 

CHUCK GILLMAN

Director

Mr. Charles M. Gillman is the head of the IDWR Multi-Family Investment Office. The office employs a team of analysts with expertise in analyzing and investing in publicly-traded companies that require operational enhancement and improvement in corporate capital allocation.

Mr. Gillman’s mandate is Constructive Value Creation. His team has had many years of experience working together to invest family-office capital into publicly-traded companies.  His organization evolved from experience in the 1990’s designing operational turnarounds of US and International companies while at McKinsey and Company.

Mr. Gillman’s clients at McKinsey benefitted from specific measures taken to improve working-capital turnover and grow those operating units that had the highest return on invested capital while shrinking those operating units that had negative returns on invested capital.  Groups formed by Mr. Gillman often constitute the largest or second largest shareholder in the companies that he invests in.  Mr. Gillman is a Summa Cum Laude graduate of the Wharton School.

 

JOHN W. SAYWARD

Director

John W. Sayward is a career Health care and pharmaceutical executive. Most recently, he served as the CEO of Hera Pharmaceuticals Inc., a preclinical pharmaceutical business with a focus on cervical cancer. He was a Partner at Nippon Heart Hospital, LLC from September 2005 to January 2007 which was formed to build and manage cardiovascular care hospitals in Japan. From 2002 to 2005, Mr. Sayward was the Executive Vice President and CFO of LMA North America Inc., a medical device business focused on patient airway management. From 1996 to 2001, Mr. Sayward served as the Executive Vice President of Finance and CFO and Treasurer at SICOR Inc., and was elected to their Board of Directors in 1998. Previous to the above, he served in various management positions with Baxter Healthcare. He received a B.A. in History from Northwestern University in 1973 and a Master of Management from the Kellogg School of Management at Northwestern University in 1975.

 

MATT MOLCHAN

President, Chief Executive Officer and Director, Digirad Corporation

Matt Molchan has held a variety of increasing responsibility roles since he joined Digirad in May 2007 via the acquisition of Ultrascan, Inc., the southeast’s largest mobile ultrasound business. These roles include Chief Operating Officer of Digirad Ultrascan Solutions from May 2007 to January 2012, President of Digirad Imaging Solutions until January 2013, President of Digirad beginning January 2013, and most recently Chief Executive Officer of Digirad since July 2013.

Prior to joining Ultrascan, Inc., he held various executive level positions in business development, finance and operations at Somera, Inc. and Equifax, Inc. He holds a Bachelor of Science degree in Economics from the United States Air Force Academy and a Masters of Business Administration in Finance from the University of Southern California.

Digirad — Revolutionary solid-state nuclear cardiology equipment and services.

Digirad delivers diagnostic expertise. As Needed. When Needed. Where Needed.